Zenas BioPharma (ZBIO) to Release Quarterly Earnings on Thursday

Zenas BioPharma (NASDAQ:ZBIO) will likely be announcing its Q2 2025 results before the market opens on Thursday, August 21st. Analysts expect the company to announce earnings of ($1.02) per share and revenue of $1.25 million for the quarter. Investors may visit the the company’s upcoming Q2 2025 earningresults page for the latest details on the call scheduled for Tuesday, August 12, 2025 at 7:00 AM ET.

Zenas BioPharma (NASDAQ:ZBIO) last announced its earnings results on Tuesday, August 12th. The company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.23).

Zenas BioPharma Stock Performance

Shares of ZBIO opened at $15.85 on Wednesday. Zenas BioPharma has a one year low of $5.83 and a one year high of $26.25. The stock has a 50-day moving average price of $12.92. The firm has a market capitalization of $667.44 million and a PE ratio of -4.46.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Wedbush reaffirmed an “outperform” rating and set a $35.00 target price on shares of Zenas BioPharma in a research note on Thursday, May 15th. Wall Street Zen cut Zenas BioPharma from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Zenas BioPharma in a research note on Friday, May 16th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $36.67.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ZBIO. Sei Investments Co. bought a new position in Zenas BioPharma during the second quarter valued at about $118,000. Bank of America Corp DE lifted its position in Zenas BioPharma by 32.3% during the 2nd quarter. Bank of America Corp DE now owns 13,991 shares of the company’s stock worth $136,000 after acquiring an additional 3,412 shares during the last quarter. Rhumbline Advisers lifted its position in Zenas BioPharma by 71.3% during the 2nd quarter. Rhumbline Advisers now owns 19,721 shares of the company’s stock worth $191,000 after acquiring an additional 8,207 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in Zenas BioPharma by 4.6% during the 2nd quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock worth $3,621,000 after acquiring an additional 16,461 shares during the last quarter.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.